Edition:
United States

ReNeuron Group PLC (RQE.L)

RQE.L on London Stock Exchange

2.35GBp
--
Change (% chg)

-- (--)
Prev Close
2.35
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
3,270,641
52-wk High
3.71
52-wk Low
2.25

Latest Key Developments (Source: Significant Developments)

ReNeuron Group plc announces placing
Friday, 10 Jul 2015 02:01am EDT 

ReNeuron Group plc:Announces that it has raised a total of 68.4 million pound, before expenses, through a conditional placing that will enable the company to build on the considerable recent progress achieved across its therapeutic programmes.  Full Article

ReNeuron receives fast track designation
Friday, 22 May 2015 02:01am EDT 

ReNeuron Group Plc:Says FDA grants Fast Track designation to ReNeuron's retinitis pigmentosa cell therapy candidate.  Full Article

ReNeuron Group plc gets FDA approval for start of phase I/II trial
Tuesday, 5 May 2015 02:01am EDT 

ReNeuron Group plc:Announces that it has received regulatory approval from the US Food and Drug Administration (FDA) to commence a Phase I/II clinical trial in the US with its human Retinal Progenitor Cell (hRPC) therapy candidate for retinitis pigmentosa (RP).Says RP is a group of hereditary diseases of the eye that lead to progressive loss of sight due to cells in the retina becoming damaged and eventually dying.Says Phase I/II clinical trial will be conducted at Massachusetts Eye and Ear, Boston, a world-renowned clinical centre for the treatment of retinal diseases.Says the trial design is an open-label, dose escalation study to evaluate the safety, tolerability and preliminary efficacy of the hRPC stem cell therapy candidate in up to 15 patients with advanced RP.  Full Article

ReNeuron Group files Investigational New Drug application with the US FDA
Monday, 13 Apr 2015 02:00am EDT 

ReNeuron Group plc:Files an Investigational New Drug (IND) application with the US FDA to commence a Phase I/II clinical trial with its human Retinal Progenitor Cell (hRPC) therapy candidate for retinitis pigmentosa (RP).Proposed Phase I/II clinical trial will be conducted at Massachusetts Eye and Ear, Boston, a world-renowned clinical centre for the treatment of retinal diseases.  Full Article

More From Around the Web